Review of the ATHOS 3 trial
Northwestern EM Blog
FEBRUARY 14, 2022
The ATHOS-3 trial in 2017 explored the efficacy of angiotensin II as a vasopressor for severe vasodilatory shock. The study was designed as a phase III multicenter randomized placebo control trial taking place across 75 intensive care units in the United States from 2015 to 2017.
Let's personalize your content